CONCORD, Calif.--(BUSINESS WIRE)--July 20, 2006--Cerus Corporation (NASDAQ:CERS) today announced the Company will release its 2006 second quarter financial results on Thursday, August 3, 2006 at 4:00 P.M. EDT. The Company will host a live conference call and webcast at 4:30 P.M. EDT that same day.

To access the live teleconference, dial 800-901-5217 (U.S.) or 617-786-2964 (international) and reference passcode 60360488. To access the webcast, please log on to the Company's website at www.cerus.com.

A replay of the webcast and teleconference will be available approximately three hours after the call for five days. To access the replay, please call 888-286-8010 (U.S.) or 617-801-6888 (international) and reference passcode 97629583.

ABOUT CERUS

Cerus Corporation is developing and commercializing novel, proprietary products and technologies within the fields of immunotherapy and blood safety that are intended to provide safer, more effective medical options to patients in areas of substantial unmet medical needs. In the field of immunotherapy, the company is employing its proprietary attenuated Listeria vaccine platform to develop a series of novel therapies to treat cancer, and it is applying its proprietary Killed But Metabolically Active technology platform in research and development of prophylactic and therapeutic vaccines for infectious diseases. In the field of blood safety, the company is developing and commercializing the INTERCEPT Blood System, which is based on the company's proprietary Helinx technology and is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells.

INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation.

    CONTACT: Cerus Corporation
             Myesha Edwards, 925-288-6017

    SOURCE: Cerus Corporation